Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1500 | Cabozantinib | VEGFR2/MET | RTK | 4.6683 | 0.1837 | 0.0599 | 0.0128 | 4.9992 | 4.2912 | 0.97044 |
MDA-MB-436 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 4.6563 | 0.2431 | 0.1736 | 0.0143 | 0.6355 | 26.2348 | 0.92245 |
SUM149PT | Ipatasertib | AKT | PI3K/mTOR | 4.6451 | 0.2929 | 0.1261 | 0.0067 | 0.9023 | 6.7816 | 0.99801 |
Hs 578T | Ipatasertib | AKT | PI3K/mTOR | 4.5924 | 0.4423 | 0.2458 | 0.0093 | 0.5006 | 0.34659 | 0.98155 |
HCC70 | Cediranib | VEGFR/cKIT | RTK | 4.5386 | -0.3262 | 0.0890 | 0.0440 | 2.2440 | 7.4053 | 0.99062 |
SUM1315MO2 | Cabozantinib | VEGFR2/MET | RTK | 4.5316 | 0.1095 | 0.1089 | 0.0163 | 1.1058 | 12.2361 | 0.99069 |
HCC70 | Alpelisib | PI3Ka | PI3K/mTOR | 4.4987 | 0.0981 | 0.1182 | 0.0196 | 1.0448 | 12.8744 | 0.95143 |
HCC1419 | Bleomycin | Radiation | Misc | 4.4662 | 0.3545 | 0.1588 | -0.0001 | 0.8100 | 4.0786 | 0.85928 |
MDA-MB-468 | Dasatinib | BCR/ABL | MAPK/nRTK | 4.4311 | 0.3393 | 0.1447 | 0.0458 | 0.7091 | 5.6436 | 0.97277 |
PDX1258 | Ipatasertib | AKT | PI3K/mTOR | 4.4024 | 0.3985 | 0.1556 | 0.0120 | 0.7553 | 1.2185 | 0.94717 |
SUM159PT | Alpelisib | PI3Ka | PI3K/mTOR | 4.3125 | 0.2818 | 0.1409 | 0.0003 | 0.7761 | 8.5413 | 0.99788 |
MCF 10A | Cisplatin | Chemo | Chemotherapy | 4.2937 | 0.3794 | 0.0952 | 0.0149 | 2.1287 | 2.4561 | 0.99519 |
MDA-MB-453 | PF-4708671 | p70S6K | PI3K/mTOR | 4.291 | 0.0482 | 0.0418 | 0.0294 | 4.9998 | 4.2285 | 0.98022 |
CAMA-1 | TGX221 | PI3Kb | PI3K/mTOR | 42.7345 | 0.8500 | 0.0067 | 0.0034 | 0.9968 | 118.889 | 0.79474 |
HCC1428 | Bleomycin | Radiation | Misc | 4.2581 | 0.2173 | 0.1780 | 0.0166 | 0.7393 | 18.8191 | 0.91689 |
HCC1428 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 4.2249 | 0.1734 | 0.1438 | 0.0192 | 0.8693 | 14.9521 | 0.96527 |
MDA-MB-134-VI | Cediranib | VEGFR/cKIT | RTK | 4.2103 | -0.9999 | 0.0977 | 0.0979 | 5.0000 | 5.2449 | 0.99321 |
MDA-MB-468 | PF-4708671 | p70S6K | PI3K/mTOR | 4.1732 | 0.0813 | 0.1176 | 0.0094 | 1.1782 | 8.8804 | 0.99743 |
T47D | Cediranib | VEGFR/cKIT | RTK | 4.1027 | -0.6403 | 0.1246 | 0.0754 | 2.9281 | 5.9706 | 0.99504 |
HCC1954 | Cediranib | VEGFR/cKIT | RTK | 4.092 | -0.3202 | 0.0756 | 0.0534 | 4.9589 | 4.5507 | 0.99308 |
HCC1428 | ABT-737 | Bcl2/XL | Misc | 4.0616 | 0.2431 | 0.1194 | 0.0716 | 1.0222 | 5.0858 | 0.98165 |
Hs 578T | Saracatinib | SRC | MAPK/nRTK | 4.0375 | 0.1890 | 0.1594 | 0.0291 | 0.7110 | 18.9291 | 0.97543 |
PDX1328 | Bleomycin | Radiation | Misc | 4.0022 | 0.3061 | 0.1994 | 0.0033 | 0.4524 | 45.3783 | 0.95786 |
BT-549 | Abemaciclib | CDK4/6 | Cell cycle | 3.9707 | 0.0333 | 0.1267 | 0.0188 | 1.2825 | 7.5655 | 0.99654 |
T47D | Saracatinib | SRC | MAPK/nRTK | 3.9647 | 0.3892 | 0.1722 | 0.0087 | 0.6928 | 1.6318 | 0.9752 |